ArticleCureus2025
Potential of a Novel Patient-Reported Outcome Assessment Method Utilizing Illustrations in Rheumatoid Arthritis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Residual symptom absence assessed by Okomarigoto Sheet is independently associated with patient-acceptable symptom state beyond inflammation in rheumatoid arthritis.Clinical rheumatology · 2026Article
- Usefulness of the illustrated patient-reported outcome tool 'Okomarigoto Sheet' for symptom expression and communication in patients with rheumatoid arthritis.EULAR rheumatology open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe investigated whether the "Okomarigoto sheet," a novel patient-reported outcome measure that utilizes illustrations, correlates with disease activity and the Health Assessment Questionnaire Disability Index (HAQ-DI) in rheumatoid arthritis.
methodsThe Okomarigoto sheet comprises five items each for morning stiffness, pain, and fatigue. Individual items are scored as follows: severe symptoms = 2, mild symptoms = 1, no symptoms = 0. The total score ranges from 0 to 30; higher scores indicate greater symptom burden. Correlations between Okomarigoto sheet scores, disease activity scores, and the HAQ-DI were analyzed in 332 patients. Scores were compared between patients in remission (HAQ-DI ≤ 0.5) and not in remission.
resultsCorrelations between the total Okomarigoto sheet score and Disease Activity Score using 28-joint count C-reactive protein, Clinical Disease Activity Index, and Simplified Disease Activity Index were 0.488, 0.591, and 0.572, respectively. The correlation between the total Okomarigoto sheet score and HAQ-DI was 0.593. The mean Okomarigoto sheet score was significantly lower in patients achieving HAQ-DI remission compared to those not in remission (2.47 vs. 10.4, respectively; p < 0.01).
conclusionsThis novel patient-reported outcome measure performed comparably to existing measures, correlating strongly with disease activity and disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.